# EDGAR Filing Document

**Accession Number:** 0001875091
**File Stem:** 0001213900-26-047292
**Filing Date:** 2026-4
**Character Count:** 2938
**Document Hash:** ee23fec0f84a48eaf39ca5d72fba965b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-047292.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001213900-26-047292

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260424

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260424

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuroSense Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001875091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41084
- **FILM NUMBER:** 26890751

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562
- **BUSINESS PHONE:** 972-9-9531142

**MAIL ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of April 2026

Commission File Number: 001-41084

**NeuroSense Therapeutics Ltd.**<br> (Translation of registrant's name into English)

**NeuroSense Therapeutics Ltd.**

**11 HaMenofim Street, Building B<br> Herzliya 4672562 Israel<br> +972-9-7996183**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**Explanatory Note**

On April 24, 2026, NeuroSense Therapeutics Ltd. (the "Company") announced that Dr. Ferenc Tracik, M.D., will step down from his role as Chief Medical Officer, effective April 27, 2026. Dr. Tracik will continue to support the Company as an independent advisor.

Dr. Tracik's departure is not the result of any disagreement with the Company on matters relating to its operations, policies, or practices.

In his advisory capacity, Dr. Tracik will contribute to ongoing clinical development activities and provide strategic medical guidance on the Company's PrimeC program, including in connection with the upcoming Pre-NDS meeting with Health Canada.

The Company thanks Dr. Tracik for his leadership and contributions and looks forward to continuing to benefit from his expertise.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NeuroSense Therapeutics Ltd.** | **NeuroSense Therapeutics Ltd.** |
| Date: April 24, 2026 | By: | /s/ Alon Ben-Noon |
|  |  | Alon Ben-Noon |
|  |  | Chief Executive Officer |

---